• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model

tetano

Editor, Senior Moderator
PLoS One


. 2024 Jun 20;19(6):e0290909.
doi: 10.1371/journal.pone.0290909. eCollection 2024. No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model

Douglas S Reed[SUP] 1 2 [/SUP], Anita K McElroy[SUP] 1 3 [/SUP], Dominique J Barbeau[SUP] 1 3 [/SUP], Cynthia M McMillen[SUP] 1 4 [/SUP], Natasha L Tilston-Lunel[SUP] 1 5 [/SUP], Shamkumar Nambulli[SUP] 1 6 [/SUP], Emily Cottle[SUP] 1 [/SUP], Theron C Gilliland[SUP] 1 [/SUP], Hasala Rannulu[SUP] 1 [/SUP], Jeneveve Lundy[SUP] 1 [/SUP], Emily L Olsen[SUP] 1 [/SUP], Katherine J O'Malley[SUP] 1 [/SUP], Mengying Xia[SUP] 1 [/SUP], Amy L Hartman[SUP] 1 4 [/SUP], Thomas C Luke[SUP] 7 [/SUP], Kristi Egland[SUP] 7 [/SUP], Christoph Bausch[SUP] 7 [/SUP], Hua Wu[SUP] 7 [/SUP], Eddie J Sullivan[SUP] 7 [/SUP], William B Klimstra[SUP] 1 2 [/SUP], W Paul Duprex[SUP] 1 6 [/SUP]



Affiliations
Abstract

Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-dependent enhancement (ADE) of disease as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral/ocular) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7-10 days post-infection. To evaluate the potential for ADE, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2.


 
Back
Top Bottom